New immunosuppressive regimens in lung transplantation

European Respiratory Journal

Volumn 10, Issue 11, 1997, Pages 2630-2637

  Briffa, N ^a   Morris, R E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunosuppressive drugs; Lung transplantation

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; XENOBIOTIC AGENT;

GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LUNG; LUNG TRANSPLANTATION; LYMPH NODE IRRADIATION; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW; SURVIVAL;

BRONCHIOLITIS OBLITERANS; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION;

EID: 0031458099     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10112630     Document Type: Review

References (51)

1. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306: 557-564.
2. Hosenpud JD, Novick RJ, Bennett LE, Keck BM, Fiol B, Daily OP. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official report. J Heart Lung Transplant 1996; 15: 655-674.
3. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110: 4-14.
4. Tazelaar HD, Yousem SA. The pathology of combined heart-lung transplantation: an autopsy study. Hum Pathol 1988; 19: 1403-1416.
5. Keller CA, Cagle PT, Brown RW, Noon G, Frost AE. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest 1995; 107: 973-980.
6. Reichenspurner H, Girgis RE, Robbins RC, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg 1995; 60: 1845-1853.
7. Kriett JM, Smith CM, Hayden AM, et al. Lung transplantation without the use of antilymphocyte antibody preparations. J Heart Lung Transplant 1993; 12: 915-923.
8. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts [see comments]. N Engl J Med 1990; 322: 1175-1182.
9. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997; 63: 33-38.
10. Girault D, Haloun A, Viard L, et al. Sandimmun neoral improves the bioavailability of cyclosporin A and decreases inter-individual variations in patients affected with cystic fibrosis. Transplant Proc 1995; 27: 2488-2490.
11. Mikhail G, Eadon H, Leaver N, et al. An investigation of the pharmacokinetics, toxicity, and clinical efficacy of neoral cyclosporin in cystic fibrosis patients. Transplant Proc 1997; 29: 599-601.
12. Morris RE. New Immunosuppressive Drugs. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo, W.B. Saunders Company, 1995.
13. Rial MC, Frias S, Argento J, Tessler J, Casadei D. Fermentation, extraction and chemical and biological characterization. Transplant Proc 1997; 29: 292-293.
14. The International Society for Heart and Lung Transplantation 17th annual meeting and scientific sessions. London, England, April 2-5, 1997. Abstracts. J Heart Lung Transplant 1997; 16: 41-142.
15. Niese D. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group. Transplant Proc 1995; 27: 1849-1856.
16. Gotoh T, Nakahara K, Nishura T, et al. Convenience of level of cyclosporine-Neoral at time 3 to determine the area under curve in renal transplant. J Antibiotics 1982; 35: 1286-1292.
17. Sigal N, Dumont F. Cyclosporin A, FK 506 and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann Rev Immunol 1992; 10: 519-560.
18. Schreiber S, Crabtree G. The mechanism of action of cyclosporin A and FK 506. Immunol Today 1992; 13: 136-142.
19. Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK506 and cyclosporine A. Ann NY Acad Sci 1993; 696: 9-19.
20. Hausen B, Morris ER. Review of immunosuppression for lung transplantation - novel drugs, new uses for conventional immunosuppressants, and alternative strategies. Clin Chest Med 1997; 18: 353-366.
21. Backman L, Nicar M, Levy M, et al. FK 506 trough levels in whole blood and plasma in liver transplant patients. Transplantation 1994; 57: 519-525.
22. Hirai T, Wada H, Hasegawa S, et al. The immunosuppressive effect of FK 506 on canine lung transplantation. J Thorac Cardiovasc Surg 1992; 103: 1127-1135.
23. Fujisawa T, Saitoh Y, Urabe N, et al. Dose study of the immunosuppression of FK506 in canine allo-transplantation. Surg Today 1993; 23: 338-343.
24. Komatsu K, Youm W, Konishi H, et al. Prolonged survival of hamster-to-rat pulmonary xenografts by tacrolimus (FK506) and cyclophosphamide. J Heart Lung Transplant 1996; 15: 722-727.
25. European FK506 Multicentre Liver Study Group. Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. Transplant Proc 1994; 26: 3260-3263.
26. Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up of an open-label trial of FK-506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61: 1576-1581.
27. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995; 60: 1384-1388.
28. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60: 580-585.
29. Steinmuller TM, Graf KJ, Schleicher J, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism: a randomized trial. Transplantation 1994; 58: 669-674.
30. Gosio B. Ricerche Batteriologiche e chimiche sulle alterazioni del mats. Revista d'Igiene e Sanita Pubblica Ann 1896; 7: 825-868.
31. Nelson P, Eugui E, Allison AC. Synthesis and immunosuppressive activity of some side chain variants of mycophenolic acid. J Med Chem 1990; 33: 833-838.
32. Morris RE, Hoyt EG, Eugui E, Allison AC. Prolongation of rat heart allograft survival by RS-61443. Surg Forum 1989; 40: 337-338.
33. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8: 710-720.
34. Laurent AF, Dumont S, Poindron P, Muller CD. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol 1996; 24: 59-67.
35. Halloran, P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39-47.
36. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
37. Morris R, Meiser B. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989; 17: 609-610.
38. Calne R, Collier D, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2: 227.
39. Sabatini D, Erdjument-Bromage H, Lui M, et al. RAFT-1: a mammalian protein that binds to FKBP12 in a rapamycin dependent fashion and is homologous to yeast cells. Cell 1994; 78: 35-43.
40. Brattstrom C, Tyden G, Sawe J, Herlenius G, Claesson K, Groth CG. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 1996; 28: 985-986.
41. Program issue. The International Society for Heart Transplantation eleventh annual meeting and scientific sessions. April 7-9, 1991, Paris, France. J Heart Lung Transplant 1991; 10: 133-200.
42. The International Society for Heart and Lung Transplantation 16th annual meeting and scientific sessions. New York, March 15-18, 1996. Abstracts. J Heart Lung Transplant 1996; 15: S1-114.
43. Morris RE, Huang X, Gregory CR, et al. Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 1995; 27: 2068-2069.
44. Kahan B. Sirolimus: a new agent for clinical renal transplantation. Transplant Proceedings 1997; 29: 48-50.
45. Wahlers T, Haverich A, Schafers HJ, et al. Chronic rejection following lung transplantation. Incidence, time pattern and consequences. Eur J Cardiothorac Surg 1993; 7: 319-324.
46. Cahill BC, O'Rourke MK, Strasburg KA, et al. Methotrexate for lung transplant recipients with steroid-resistant acute rejection. J Heart Lung Transplant 1996; 15: 1130-1137.
47. Snell GI, Esmore DS, Williams TJ, Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation. Chest 1996; 109: 874-878.
48. Ross DJ, Jordan SC, Nathan SD, Kass RM, Koerner SK. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials. Chest 1996; 109: 870-873.
49. Iacono AT, Keenan RJ, Duncan SR, et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med 1996; 153: 1451-1455.
50. Dusmet M, Maurer J, Winton T, Kesten S. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 1996; 15: 948-954.
51. Valentine VG, Robbins RC, Wehner JH, Patel HR, Berry GJ, Theodore J. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest 1996; 109: 1184-1189.